第一节 重要提示 1.1本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规 划，投资者应当到www.sse.com.cn网站仔细阅读半年度报告全文。 1.2本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 1.3公司全体董事出席董事会会议。 登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：600586 公司简称：金晶科技 第二节 公司基本情况 2.1公司简介 ■ 2.2主要财务数据 单位：元 币种：人民币 ■ 2.3前10名股东持股情况表 1.4本半年度报告未经审计。 1.5董事会决议通过的本报告期利润分配预案或公积金转增股本预案 本报告期不进行利润分配或公积金转增股本。 单位: 股 ■ 2.4截至报告期末的优先股股东总数、前10名优先股股东情况表 □适用 √不适用 2.5控股股东或实际控制人变更情况 □适用 √不适用 2.6在半年度报告批准报出日存续的债券情况 □适用 √不适用 第三节 重要事项 公司应当根据重要性原则，说明报告期内公司经营情况的重大变化，以及报告期内 ...

证券代码：301338 证券简称：凯格精机 公告编号：2025-023 经审议，董事会认为公司《2025 年半年度募集资金存放与使用情况的专项 报告》真实、准确、完整地反映了公司 2025 年上半年的募集资金存放与使用情 况。《2025 年半年度募集资金存放与使用情况的专项报告》内容真实、准确、 完整，2025 年半年度募集资金的存放与使用均符合中国证监会、深圳证券交易 所对募集资金存放和使用的相关要求，不存在违规使用募集资金的行为，亦不存 在改变或者变相改变募集资金投向和损害股东利益的情形。 本议案已经公司第二届董事会审计委员会第十五次会议审议通过。 东莞市凯格精机股份有限公司 第二届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 东莞市凯格精机股份有限公司（以下简称"公司"）第二届董事会第十七次 会议于 2025 年 8 月 21 日在公司会议室以现场结合通讯方式召开。本次会议通知 于 2025 年 8 月 11 日以书面、邮件等形式发出，会议应出席董事 5 人，实际出席 董事 5 人，其中谢园保先生、王钢先生以通讯方式表决。会 ...

证券代码：000682 证券简称：东方电子 公告编号：2025-28 东方电子股份有限公司 第十一届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 表决结果：表决通过。其中，同意 9 票；反对 0 票；弃权 0 票。 与会董事认真听取了《公司 2025 年半年度总经理工作报告》，认为该报告 客观、真实地反映了 2025 年上半年公司经营管理团队落实董事会及股东会决议、 公司生产经营、执行公司各项制度等方面的工作成就。 表决结果：表决通过。其中，同意 9 票；反对 0 票；弃权 0 票。 《公司 2025 年中期利润分配方案的公告》同日刊登在《中国证券报》、《证 券时报》及巨潮资讯网（www.cninfo.com.cn）。 表决结果：表决通过。同意 9 票；反对 0 票；弃权 0 票。 一、会议召开情况 东方电子股份有限公司（以下简称"公司"）第十一届董事会第十四次会 议于 2025 年 8 月 22 日以现场加网络的方式在公司会议室召开，会议通知于 2025 年 8 月 12 日以电子邮件的方式通知全体董事。本次会议是定期会议，应参 ...

东莞市凯格精机股份有限公司（以下简称"公司"）第二届监事会第十六次 会议于 2025 年 8 月 21 日在公司会议室以现场方式召开。本次会议通知于 2025 年 8 月 11 日以书面、邮件等形式发出，会议应出席监事 3 人，实际出席监事 3 人。会议由监事会主席张艳女士召集并主持，本次会议的召集、召开符合《公司 法》和《公司章程》的有关规定，会议合法有效。 一、监事会会议审议情况 经过各位监事认真审议，本次会议形成如下决议： 东莞市凯格精机股份有限公司 第二届监事会第十六次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：301338 证券简称：凯格精机 公告编号：2025-024 经审议，监事会认为：公司董事会编制和审议《2025 年半年度报告》及《2025 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容 真实、准确、完整地反映了公司的实际情况，不存在虚假记载、误导性陈述或者 重大遗漏。因此，全体监事一致同意《2025 年半年度报告》全文及《2025 年半 年度报告摘要》的内容。 具体内容详见公司同日披露于巨 ...

北京海新能源科技股份有限公司（以下简称"公司"）于2025年08月08日召开 了第六届董事会第二十五次会议，以5票同意、0票反对、0票弃权的表决结果审 议通过了《关于公司全资子公司沈阳三聚凯特催化剂有限公司申请银行授信额度 暨关联交易的议案》，关联董事于志伟先生、王笛女士、姜骞先生、李雪梅女士 对该议案回避表决。该项议案提交董事会审议前，已经公司2025年第六次独立董 事专门会议以3票同意、0票反对、0票弃权的表决结果审议通过。现就本次关联 交易的具体情况公告如下： 北京海新能源科技股份有限公司 证券代码：300072 证券简称：海新能科 公告编号：2025-031 北京海新能源科技股份有限公司 关于公司全资子公司沈阳三聚凯特催化剂有限公司申请银 行授信额度暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、关联交易概述 公司全资子公司沈阳三聚凯特催化剂有限公司（以下简称"三聚凯特"）为 满足其经营需要，拟向中国建设银行股份有限公司沈阳铁西支行（以下简称"建 行铁西支行"）申请不超过人民币1.80亿元综合授信额度，其中敞口额度不超过 种为：流 ...

Group 1 - The company has signed a maximum guarantee contract with Industrial Bank Co., Ltd. Wenzhou Branch to provide a joint liability guarantee for a bank credit limit of 44 million yuan for its wholly-owned subsidiary, Zhejiang Fuda Alloy Material Technology Co., Ltd. [2][4] - The guarantee period is three years from the expiration of the debt performance period under the main contract [7][11]. - The company has approved a total credit limit of up to 2.8 billion yuan for 2025, which can be used for mutual guarantees among the company and its subsidiaries [3][12]. Group 2 - As of the announcement date, the total guarantee balance for the company and its subsidiaries is 1.2201591 billion yuan, accounting for 125.67% of the latest audited net assets [13]. - The total guarantee amount is 1.969 billion yuan, which represents 202.80% of the latest audited net assets [13]. - All guarantees provided are for wholly-owned subsidiaries, and there are no overdue guarantees [13].

Fund Utilization - The company has approved the use of excess raised funds amounting to 50 million RMB for permanent working capital supplementation as of January 18, 2023 [2] - An additional 159.901 million RMB of excess funds has been allocated for the investment in the "New Energy Vehicle Precision Transmission Gear Manufacturing Project," with 121.908 million RMB actually utilized by 2024 [2] - The company has also approved the temporary use of 50 million RMB of idle raised funds for working capital, with 20 million RMB actually utilized and repaid by December 31, 2024 [2] - The company has utilized 30 million RMB of excess raised funds for cash management, which has been redeemed by December 31, 2024 [3] Project Performance - There have been no abnormal situations reported regarding the investment projects funded by raised capital [4] - Certain projects, such as the R&D center upgrade, do not directly generate benefits but are aimed at enhancing the company's long-term competitiveness [5] - The company has not changed any of the investment projects funded by raised capital [6] Disclosure and Governance - The company has reported no significant issues in the use and disclosure of raised funds for the year [7] - The company has revised its articles of association and governance systems to comply with the latest legal requirements and improve operational standards [35][36] Credit Facility - The company has applied for a comprehensive credit facility of up to 1.256 billion RMB from various banks [9] - The company plans to increase this credit facility by an additional 1.4 billion RMB, bringing the total to 2.656 billion RMB [10] - The credit facility will be secured by the company's legally owned assets, and the actual financing amount will depend on operational needs [10][12] Shareholder Meeting - The company will hold its first extraordinary general meeting of 2025 on August 21, 2025, to discuss various resolutions [15][16] - The meeting will allow for both on-site and online voting, with specific procedures outlined for participation [17][22] Investor Communication - The company will hold a half-year performance briefing on August 15, 2025, to discuss its operational results and financial status [33] - Investors are encouraged to submit questions in advance for discussion during the briefing [34]

Overview - The company, Bluestar Medical Co., Ltd., plans to apply for a total credit limit of up to RMB 1.71 billion for 2025, which includes various types of financing such as working capital loans and bank guarantees [1][3] Credit and Guarantee Situation - The company and its subsidiaries will provide guarantees totaling no more than RMB 1.71 billion, with RMB 1.544 billion allocated for subsidiaries with a debt-to-asset ratio below 70% and RMB 166 million for those at or above 70% [1][3] - The guarantee period is valid for 12 months from the date of the shareholders' meeting resolution [1] Recent Developments - Recently, the company applied for a credit limit of up to RMB 50 million from Zheshang Bank, securing it with a pledge of a RMB 50 million time deposit [3][7] - This guarantee does not exceed the approved limit from the recent board and shareholders' meetings, thus no additional meetings are required for approval [3] Financial Data - As of the announcement date, the total maximum guarantee amount for the company and its subsidiaries is RMB 3,803.58 million, which accounts for 46.46% of the company's audited net assets for 2024 [8] - The company has no overdue guarantees or any litigation related to guarantees [9] Company Information - Bluestar Medical Co., Ltd. was established on December 2, 2002, with a registered capital of RMB 1,007.13 million [4][5] - The company specializes in the production of PVC gloves, nitrile gloves, and various medical devices [5]

Core Insights - As of the end of June, banks in Guangdong have provided credit for 1,812 "white list" projects amounting to 1,091.829 billion yuan, with 832.796 billion yuan successfully implemented, maintaining the top position in the country for project count, credit amount, and implementation amount [1][1][1] - Real estate credit is showing steady growth, with real estate development loans and personal housing loans increasing by 7.30% and 1.17% year-on-year, respectively [1][1][1]

Core Viewpoint - Shanghai Bank has approved a credit limit of RMB 2.1 billion for Postal Consumer Finance Co., Ltd., which is valid for one year, primarily for interbank borrowing, interbank lending, and bond investment [1] Group 1 - The credit limit granted to Postal Consumer Finance Co., Ltd. is RMB 2.1 billion [1] - The approval was made during the seventh meeting of the board of directors in 2025 [1] - The credit facility is intended for various financial activities including interbank borrowing and bond investment [1] Group 2 - Related directors Gu Jinshan and Tao Hongjun abstained from voting on the related party transaction [1]